BTAI vs. KPTI, EBS, MGNX, RANI, ENTA, FHTX, IMMP, ACRV, HOWL, and ELYM
Should you be buying BioXcel Therapeutics stock or one of its competitors? The main competitors of BioXcel Therapeutics include Karyopharm Therapeutics (KPTI), Emergent BioSolutions (EBS), MacroGenics (MGNX), Rani Therapeutics (RANI), Enanta Pharmaceuticals (ENTA), Foghorn Therapeutics (FHTX), Immutep (IMMP), Acrivon Therapeutics (ACRV), Werewolf Therapeutics (HOWL), and Eliem Therapeutics (ELYM). These companies are all part of the "pharmaceutical preparations" industry.
BioXcel Therapeutics (NASDAQ:BTAI) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, community ranking, media sentiment and profitability.
BioXcel Therapeutics has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 0.16, meaning that its share price is 84% less volatile than the S&P 500.
Karyopharm Therapeutics received 288 more outperform votes than BioXcel Therapeutics when rated by MarketBeat users. Likewise, 72.05% of users gave Karyopharm Therapeutics an outperform vote while only 67.23% of users gave BioXcel Therapeutics an outperform vote.
In the previous week, BioXcel Therapeutics had 1 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 4 mentions for BioXcel Therapeutics and 3 mentions for Karyopharm Therapeutics. Karyopharm Therapeutics' average media sentiment score of 0.62 beat BioXcel Therapeutics' score of 0.29 indicating that Karyopharm Therapeutics is being referred to more favorably in the news media.
BioXcel Therapeutics currently has a consensus target price of $16.71, indicating a potential upside of 823.44%. Karyopharm Therapeutics has a consensus target price of $4.80, indicating a potential upside of 395.30%. Given BioXcel Therapeutics' higher possible upside, research analysts plainly believe BioXcel Therapeutics is more favorable than Karyopharm Therapeutics.
30.7% of BioXcel Therapeutics shares are owned by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 35.8% of BioXcel Therapeutics shares are owned by company insiders. Comparatively, 4.3% of Karyopharm Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Karyopharm Therapeutics has a net margin of -104.18% compared to BioXcel Therapeutics' net margin of -8,715.72%. Karyopharm Therapeutics' return on equity of 0.00% beat BioXcel Therapeutics' return on equity.
Karyopharm Therapeutics has higher revenue and earnings than BioXcel Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Karyopharm Therapeutics beats BioXcel Therapeutics on 11 of the 17 factors compared between the two stocks.
Get BioXcel Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BTAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioXcel Therapeutics Competitors List
Related Companies and Tools
